Prediction of CDKN 2A/B homozygous deletion status in IDH-mutant astrocytoma by radiomics nomogram
10.3969/j.issn.1002-1671.2024.11.004
- VernacularTitle:影像组学列线图预测IDH突变型星形细胞瘤CDKN 2A/B纯合缺失状态
- Author:
Linling WANG
1
;
Xinyi XU
;
Hongyu PAN
;
Liqiang ZHANG
;
Ming WEN
Author Information
1. 重庆医科大学附属第一医院放射科,重庆 400012
- Keywords:
Cyelin-Dependent Kinase Inhibitor 2A/B;
radiomics;
isocitrate dehydrogenase;
mutant astrocytoma;
nomogram
- From:
Journal of Practical Radiology
2024;40(11):1770-1774
- CountryChina
- Language:Chinese
-
Abstract:
Objective To construct a MRI-based radiomics nomogram for predicting the Cyelin-Dependent Kinase Inhibitor 2A/B(CDKN 2A/B)homozygous deletion status in patients with isocitrate dehydrogenase(IDH)-mutant astrocytoma.Methods A total of 200 patients with IDH-mutant astrocytoma(103 CDKN 2A/B homozygous deletion and 97 CDKN 2A/B non-homozygous dele-tion)were enrolled in a training cohort(n=140)and a test cohort(n=60).A total of 1 946 features were respectively extracted in tumor edema area and tumor parenchyma area,and 3 892 features were extracted in overall tumor area.All features were extracted from T2 fluid attenuated inversion recovery(T2 FLAIR)and T1 WI contrast enhancement sequences.The t test and the least absolute shrinkage and selection operator(LASSO)model were used to select radiomics features,and a radiomics nomogram was constructed by using age,gen-der and the above radiomics features.Results The t test concluded that the overall tumor radiomics signature had the best perform-ance[area under the curve(AUC):training cohort=0.951,test cohort=0.779]and the radiomics nomogram had a good ability to pre-dict the CDKN 2A/B homozygous deletion in IDH-mutant astrocytoma.The clinical usefulness of the nomogram in predicting the CDKN 2A/B homozygous deletion was further confirmed by decision curve analysis(DCA).Conclusion The nomogram combined with age,gender,and the radiomics features provides a clinically useful approach to predict the CDKN 2A/B homozygous deletion and facilitated MRI-based clinical decision-making in patients with IDH-mutant astrocytoma.
